All In Biotech

Drug Trial Radar · NCT01681992

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Immunogenicity and Safety Study of GSK Biologicals' Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life

Last checked: Nov 19, 2026Latest source record: Jan 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,538 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,538

Actual

Start

Oct 10, 2012

Primary completion

Feb 3, 2015

Study completion Aug 18, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).

Conditions

  • Measles
  • Mumps
  • Rubella
  • Measles-Mumps-Rubella Vaccine

Interventions

  • PriorixBiological

    Subjects receive one dose of either minimum (Inv\_MMR\_Min) or medium (Inv\_MMR\_Med) potency lot at Day 0 and a dose of separate potency lot (Inv\_MMR\_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.

  • M-M-R IIBiological

    Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.

  • VarivaxBiological

    Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.

  • HavrixBiological

    Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.

  • Prevnar 13Biological

    US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by Enzyme-linked Immunosorbent Assay [ELISA])Time frame: At Day 42
  2. Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA)Time frame: At Day 42
  3. Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by Plaque Reduction Neutralization Test [PRNT])Time frame: At Day 42
  4. Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA)Time frame: At Day 42
  5. Anti-measles Virus Antibody Concentrations (by ELISA)Time frame: At Day 42
  6. Anti-mumps Virus Antibody Concentrations (by ELISA)Time frame: At Day 42
  7. Anti-mumps Virus Antibody Concentrations (by PRNT)Time frame: At Day 42
  8. Anti-rubella Virus Antibody Concentrations (by ELISA)Time frame: At Day 42

Locations

81 sites in 7 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    West Covina, California

  • GSK Investigational Site

    Altamonte Springs, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    Naples, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Muncie, Indiana

  • GSK Investigational Site

    New Albany, Indiana

  • GSK Investigational Site

    West Des Moines, Iowa

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Annapolis, Maryland

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Frederick, Maryland

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    Lincoln, Nebraska

  • GSK Investigational Site

    Lincoln, Nebraska

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Clyde, North Carolina

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    Toledo, Ohio

  • GSK Investigational Site

    Youngstown, Ohio

  • GSK Investigational Site

    Gresham, Oregon

  • GSK Investigational Site

    Johnstown, Pennsylvania

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Layton, Utah

  • GSK Investigational Site

    Springville, Utah

  • GSK Investigational Site

    St. George, Utah

  • GSK Investigational Site

    Midlothian, Virginia

  • GSK Investigational Site

    Richmond, Virginia

  • GSK Investigational Site

    Ellensburg, Washington

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.